Citations

Clear

815 citation(s) found for "Tang, Yu".

Integration of multi-omics data shows downregulation of mismatch repair, purin, and tubulin pathways in triple-negative chemotherapy-resistant breast tumors
Vedell, Peter T. , McLaughlin, Sarah A., Northfelt, Donald W. , Aspitia, Alvaro Moreno, Gray, Richard J. , Weinshilboum, Richard M. , Wang, Liewei , Tang, Xiaojia , Thompson, Kevin J. , Kalari, Krishna R. , Sinnwell, Jason P. , Suman, Vera J. , Carter, Jodi M. , Weinshilboum, Richard M. , Boughey, Judy C. , Goetz, Matthew P.

Mayo Clinic

No container title available | August 17, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1954567/v1 Get It

AbstractBackground:Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype. Patients with TNBC are primarily treated with neoadjuvant chemotherapy (NAC). Response to NAC is prognostic, with reductions in low overall survival and disease-free survival rates in those patients who do not achieve pathological complete response (pCR). Based on this premise, we focused on patients with residual disease and hypothesized that paired analysis of primary and residual TNBC tumors following NAC could identify unique biomarkers associated with post-NAC recurrence.Methods and Results: We investigated 24 TNBC tumors from 12 patients with pre- and post-NAC data, including four patients who recurred shortly after surgery(<24 months) and eight who remained recurrence-free (> 48 months). These tumors were collected from a prospective NAC breast cancer study (BEAUTY) conducted at the Mayo Clinic. Differential expression analysis of pre-NAC biopsies showed minimal gene expression differences between early recurrent and non-recurrent TNBC tumors; however, post-NAC samples demonstrated a significant alteration in expression patterns in response to intervention. Topological-level differences associated with early recurrence were implicated in 251 gene sets, and an independent assessment of microarray gene expression data from the paired NAC I-SPY1 trial confirmed 56 genesets. Underlying these 56 gene sets, 113 genes were observed to be differentially expressed in the I-SPY1 and BEAUTY post-NAC studies. An independent (n=392) breast cancer data set with relapse-free survival (RFS) data was used to refine our gene list to a 17 gene signature. A three-fold cross-validation analysis of the gene signature with the combined BEAUTY and I-SPY1 data yielded an average AUC of 0.88 for six machine learning models. Due to the limited studies with pre-and post-NAC TNBC tumor data, further validation of the signature is needed.Conclusion:Analysis of multi-omics data from post-NAC TNBC chemoresistant tumors showed downregulation of mismatch repair, purin, and tubulin pathways. Additionally, weidentified a 17 gene signature in TNBC associated with post-NAC recurrence enriched with down-regulation of immune genes.
Young serum protects against memory impairment in APP/PS1 transgenic mice by blocking neutrophil infiltration
Guo, Kaihua , Qi, Fangfang , Zuo, Zejie , Wu, Tong , Liu, Hao , Tang, Jiaoling , Wang, Qingbo , Xie, Yufeng , Tan, Liren, Yang, Yunjie , Zhang, Xiaoran , Xu, Jie , Yao, Zhibin , Wang, Shengwen , Qi, Fangfang , Hu, Kaishun , Wang, Rui Ting , Wu, Long‐Jun

Mayo Clinic

No container title available | August 9, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1906482/v1 Get It

Abstract Activation of innate immunity in the brain is a prominent feature of Alzheimer's disease (AD). The present study investigated the regulation of innate immunity by young serum in a transgenic AD mouse model. We found that young serum significantly reduced the number of neutrophils and microglial reactivity in the brains of APP/PS1 mice. Neutrophil depletion via Ly6G neutralizing antibodies mimicked the benefits of young serum on AD brain functions. Serum proteomic analysis of young serum revealed significant enrichment of the factors VEGF-A and CXCL1, which are crucial for neutrophil migration and chemotaxis, leukocyte migration, and cell chemotaxis. Intravenously injected VEGF-A reversed Aβ-induced decreases in Cdk5 and increases in CXCL1 in vitro and blocked neutrophil infiltration into the AD brain. Endothelial Cdk5 overexpression conferred an inhibitory effect on CXCL1 and neutrophil infiltration and thereby restored memory in APP/PS1 mice. Our data uncover a previously unknown link between blood-derived VEGF signaling and neutrophil infiltration and provide a rationale for targeting endothelial Cdk5 signaling as a potential therapeutic strategy for AD.
Autopsy of a telephone‐based peer support intervention: Exploring participants' perspectives of and experiences with a self‐management support model for adults with type 2 diabetes from speciality care settings
Ashrafi, Shadan , Yip, Annie K. W. , Seddigh, Sorayya , Moradi, Romina, Waraich, Roop, Tang, Tricia S. , Tang, Tricia S , Deo, Neha

Mayo Clinic

Diabetic Medicine | July 29, 2022 | Volume: 39 | Issue: 10 | Pages: No page available

10.1111/dme.14924 | PMID 36097326 Get It

AbstractAimsTo explore participants' experiences with and perspective of a telephone‐based, peer‐led diabetes self‐management intervention targeting adults with type 2 diabetes (T2D) from speciality care settings. We also sought to identify areas for improvement for future iterations of the intervention.MethodsThis study recruited 25 adults with T2D from the intervention arm of a randomized controlled trial of a peer support intervention for diabetes. Individuals took part in semi‐structured interviews that explored the following topics: perceived impact of the intervention, relationship with peer leader, desirable characteristics in a peer leader, and suggestions for improving the intervention. Focus groups were recorded, transcribed, quality checked, coded, and analysed to develop themes and subthemes.ResultsFour core themes emerged: (1) importance of the ‘participant‐peer leader’ match, (2) peer leader roles and responsibilities, (3) need for flexible support models, and (4) factors affecting intervention implementation and engagement. The quality of the participant‐peer leader relationship appeared to be linked to intervention satisfaction. Beyond demographic features such as age and sex, key characteristics for forming a strong match included stage of life, lifestyle, diabetes‐related factors, and communication style.ConclusionsParticipants have unique ideas about what support should look like and preferences for how support is best delivered. Future models of peer support need to be customizable to individuals' needs and responsive to changes in life circumstances. If participants are the decision makers in the matching process, they may experience greater satisfaction and derive maximal benefits.
DNA barcoded competitive clone-initiating cell analysis reveals novel features of metastatic growth in a cancer xenograft model
Aalam, Syed Mohammed Musheer , Song, Jianning, Ray, Upasana , Weroha, S. John , Shridhar, Viji , Eaves, Connie J. , Knapp, David J. H. F. , Bakkum-Gamez, Jamie, Kannan, Nagarajan , Musheer Aalam, Syed Mohammed , Knapp, David J H F , Tang, Xiaojia , Bakkum‐Gamez, Jamie N. , Sherman, Mark E. , Kalari, Krishna R. , Kannan, Nagarajan

Mayo Clinic

NAR Cancer | July 21, 2022 | Volume: 4 | Issue: 3 | Pages: No page available

10.1093/narcan/zcac022 | PMID 35875052 Get It

Abstract A problematic feature of many human cancers is a lack of understanding of mechanisms controlling organ-specific patterns of metastasis, despite recent progress in identifying many mutations and transcriptional programs shown to confer this potential. To address this gap, we developed a methodology that enables different aspects of the metastatic process to be comprehensively characterized at a clonal resolution. Our approach exploits the application of a computational pipeline to analyze and visualize clonal data obtained from transplant experiments in which a cellular DNA barcoding strategy is used to distinguish the separate clonal contributions of two or more competing cell populations. To illustrate the power of this methodology, we demonstrate its ability to discriminate the metastatic behavior in immunodeficient mice of a well-established human metastatic cancer cell line and its co-transplanted LRRC15 knockdown derivative. We also show how the use of machine learning to quantify clone-initiating cell (CIC) numbers and their subsequent metastatic progeny generated in different sites can reveal previously unknown relationships between different cellular genotypes and their initial sites of implantation with their subsequent respective dissemination patterns. These findings underscore the potential of such combined genomic and computational methodologies to identify new clonally-relevant drivers of site-specific patterns of metastasis.
Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination
Tang, Jinyi , Zeng, Cong , Cox, Thomas M, Li, Chaofan , Son, Young Min , Cheon, In Su , Wu, Yue , Taylor, Justin J. , Chakaraborty, Rana, Johnson, Aaron J. , Schiavo, Dante , Utz, James P., Reisenauer, Janani , Midthun, David E. , Mullon, John J., Edell, Eric S. , Alameh, Mohamad‐Gabriel , Borish, Larry , Teague, W. Gerald , Kaplan, Mark H. , Kern, Ryan , Vassallo, Robert , Behl, Supriya, Taylor, Justin J , Chakraborty, Rana , Johnson, Aaron J. , Reisenauer, Janani S , Midthun, David E , Kaplan, Mark H , Weissman, Drew , Kern, R , Hu, Haitao , Vassallo, Robert , Liu, Shan-Lu , Sun, Jie , Tang, J , Li, Chaofan , Behl, Supriya , Chakaraborty, Rana, Liu, Shan-Lu , Sun, Jie

Mayo Clinic

Science Immunology | July 19, 2022 | Volume: 7 | Issue: 76 | Pages: No page available

10.1126/sciimmunol.add4853 | PMID 35857583 Get It

SARS-CoV-2 mRNA vaccination induces robust humoral and cellular immunity in the circulation; however, it is currently unknown whether it elicits effective immune responses in the respiratory tract, particularly against variants of concern (VOCs), including Omicron. We compared the SARS-CoV-2 S–specific total and neutralizing antibody responses, and B and T cell immunity, in the bronchoalveolar lavage fluid (BAL) and blood of COVID-19–vaccinated individuals and hospitalized patients. Vaccinated individuals had significantly lower levels of neutralizing antibody against D614G, Delta (B.1.617.2), and Omicron BA.1.1 in the BAL compared with COVID-19 convalescents despite robust S-specific antibody responses in the blood. Furthermore, mRNA vaccination induced circulating S-specific B and T cell immunity, but in contrast to COVID-19 convalescents, these responses were absent in the BAL of vaccinated individuals. Using a mouse immunization model, we demonstrated that systemic mRNA vaccination alone induced weak respiratory mucosal neutralizing antibody responses, especially against SARS-CoV-2 Omicron BA.1.1 in mice; however, a combination of systemic mRNA vaccination plus mucosal adenovirus-S immunization induced strong neutralizing antibody responses not only against the ancestral virus but also the Omicron BA.1.1 variant. Together, our study supports the contention that the current COVID-19 vaccines are highly effective against severe disease development, likely through recruiting circulating B and T cell responses during reinfection, but offer limited protection against breakthrough infection, especially by the Omicron sublineage. Hence, mucosal booster vaccination is needed to establish robust sterilizing immunity in the respiratory tract against SARS-CoV-2, including infection by the Omicron sublineage and future VOCs.
Beta 2-Adrenergic Receptor in Circulating Cancer-Associated Cells Predicts for Increases in Stromal Macrophages in Circulation and Patient Survival in Metastatic Breast Cancer
Gardner, Kirby P. , Cristofanilli, Massimo , Chumsri, Saranya , Lapidus, Rena, Tang, Cha‐Mei , Raghavakaimal, Ashvathi , Cristofanilli, Massimo , Adams, Daniel L.

Mayo Clinic

International Journal of Molecular Sciences | July 1, 2022 | Volume: 23 | Issue: 13 | Pages: 7299

10.3390/ijms23137299 | PMID 35806301 Get It

The usage of beta blockers in breast cancer (BC) patients is implicated in the reduction in distant metastases, cancer recurrence, and cancer mortality. Studies suggest that the adrenergic pathway is directly involved in sympathetic-driven hematopoietic activation of pro-tumor microenvironmental proliferation and tumor cell trafficking into the circulation. Cancer-associated macrophage-like cells (CAMLs) are pro-tumor polynucleated monocytic cells of hematopoietic origin emanating from tumors which may aid in circulating tumor cell (CTC) dissemination into the circulation. We examined the linkage between Beta-2 adrenergic receptor (B2AR) signaling in CAMLs and CTCs by establishing expression profiles in a model BC cell line (MDA-MB-231). We compared the model to CAMLs and CTCs found in patents. Although internalization events were observed in patients, differences were found in the expression of B2AR between the tumor cell lines and the CAMLs found in patients. High B2AR expression on patients’ CAMLs was correlated with significantly more CAMLs in the circulation (p = 0.0093), but CTCs had no numerical relationship (p = 0.1565). High B2AR CAML expression was also significantly associated with a larger size of CAMLs (p = 0.0073), as well as being significantly associated with shorter progression-free survival (p = 0.0097) and overall survival (p = 0.0265). These data suggest that B2AR expression on CAMLs is closely related to the activation, intravasation, and growth of CAMLs in the circulation.
PB1887: NETWORK META-ANALYSIS OF PROGRESSION FREE SURVIVAL IN THE TREATMENT OF RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Chanan‐Khan, Asher , Liu, T., Yang, Kaiqian, Cohen, A., Fahrbach, Kyle , Campbell, Joanna, Tang, B., Liu, T., Tang, B

Mayo Clinic

HemaSphere | June 24, 2022 | Volume: 6 | Issue: No issue available | Pages: 1766-1767

10.1097/01.hs9.0000850400.19760.77 Get It

PB1888: EFFICACY OF FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA: A BAYESIANNETWORK META-ANALYSIS.
Chanan-Khan, A., Yang, Kaiqian, Liu, T., Cohen, A., Fahrbach, K., Wang, Y., Tang, B., Chanan‐Khan, A.A., Liu, T., Fahrbach, Kyle , Tang, B

Mayo Clinic

HemaSphere | June 24, 2022 | Volume: 6 | Issue: No issue available | Pages: 1767-1768

10.1097/01.hs9.0000850404.50582.cb Get It

Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601
Tang, Ming , Schipper, Matthew J. , Sandler, Howard M. , Zumsteg, Zachary S. , Efstathiou, Jason A. , Shipley, William U. , Seiferheld, Wendy, Lukka, Himanshu, Bahary, Jean-Paul , Zietman, Anthony L., Pisansky, Thomas M. , Zeitzer, Kenneth L. , Hall, William A. , Dess, Robert T. , Lovett, R.D., Balogh, Alexander G., Feng, Felix Y. , Spratt, Daniel E. , Jackson, William C , Tang, Ming , Sandler, Howard M , Zumsteg, Zachary S , Efstathiou, Jason A , Zeitzer, Kenneth L , Hall, William A , Dess, Robert T , Feng, Felix Y , Spratt, Daniel E , Jackson, Will

Mayo Clinic

Journal of Clinical Oncology | June 23, 2022 | Volume: 40 | Issue: 27 | Pages: 3172-3179

10.1200/jco.21.02741 | PMID 35737923 Get It

PURPOSE Metastasis-free survival (MFS), but not event-free survival, is a validated surrogate end point for overall survival (OS) in men treated for localized prostate cancer. It remains unknown if this holds true in biochemically recurrent disease after radical prostatectomy. Leveraging NRG/RTOG 9601, we aimed to determine the performance of intermediate clinical end points (ICEs) as surrogate end points for OS in recurrent prostate cancer. MATERIALS AND METHODS NRG/RTOG 9601 randomly assigned 760 men with recurrence after prostatectomy to salvage radiation therapy with 2 years of placebo versus bicalutamide 150 mg daily. ICEs assessed were biochemical failure (BF) per NRG/RTOG 9601 (prostate-specific antigen nadir + 0.3-0.5 ng/mL or initiation of salvage hormone therapy; [BF1]) and NRG/RTOG 0534 (prostate-specific antigen nadir+2 ng/mL; [BF2]), distant metastasis (DM), and MFS (DM or death). Surrogacy was assessed by the Prentice criteria and a two-stage meta-analytic approach (condition one assessed at the patient level with Kendall's τ and condition two assessed by randomly dividing the entire trial cohort into 10 pseudo trial centers and calculating the average R2 between treatment hazard ratios for ICE and OS). RESULTS BF1, BF2, DM, and MFS satisfied the four Prentice criteria. However, with the two-condition meta-analytic approach, there was strong correlation between MFS and OS (τ = 0.86), moderate correlation between DM and OS (τ = 0.66), and weaker correlation between BF1 (τ = 0.25) or BF2 (τ = 0.40) and OS. Similarly, for condition two, the treatment effect of antiandrogen therapy on MFS and OS were correlated ( R2 = 0.67), but this was not true for BF1 ( R2 = 0.09), BF2 ( R2 = 0.12), or DM ( R2 = 0.18) and OS. CONCLUSION MFS is also a strong surrogate for OS in men receiving salvage radiation therapy for recurrence after prostatectomy. Caution should be used when inferring survival benefit from effects on BF in biochemically recurrent prostate cancer. Lack of comorbidity data did not allow us to assess whether BF in men with no/minimal comorbidity could serve as a surrogate for OS.
P685: REAL WORLD EVIDENCE OF IMPACT OF ATRIAL FIBRILLATION ON CLINICAL AND ECONOMIC OUTCOMES IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
Yang, K., Liu, T., Tang, B., Chanan‐Khan, Asher , Yang, K., Tang, B

Mayo Clinic

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 581-582

10.1097/01.hs9.0000845624.04306.b3 Get It